Fiche publication
Date publication
octobre 2021
Journal
Cancers
Auteurs
Membres identifiés du Cancéropôle Est :
Pr DEDIEU Stéphane
,
Dr BOULAGNON-ROMBI Camille
Tous les auteurs :
Jeanne A, Sarazin T, Charlé M, Moali C, Fichel C, Boulagnon-Rombi C, Callewaert M, Andry MC, Diesis E, Delolme F, Rioult D, Dedieu S
Lien Pubmed
Résumé
TAX2 peptide is a cyclic peptide that acts as an orthosteric antagonist for thrombospondin-1 (TSP-1) interaction with CD47. TAX2 was first described for its anti-angiogenic activities and showed anti-cancer efficacy in numerous preclinical models. Here, we aimed at providing an extensive molecular characterization of TAX2 mode of action, while evaluating its potential in ovarian cancer therapy. Multidisciplinary approaches were used to qualify a TAX2 drug candidate in terms of stability, solubility and potency. Then, efficacy studies, together with benchmark experiments, were performed in relevant mouse models of ovarian carcinoma. TAX2 peptide appears to be stable and soluble in clinically relevant solvents, while displaying a favorable safety profile. Moreover, clinical data mining allowed for the identification of TSP-1 as a relevant pharmacological target in ovarian cancer. In mice, TAX2 therapy inhibits ovarian tumor growth and metastatic dissemination, while activating anti-cancer adaptive immunity. Interestingly, TAX2 also synergizes when administered in combination with anti-PD-1 immune checkpoint inhibitiors. Altogether, our data expose TAX2 as an optimized candidate with advanced preclinical characterization. Using relevant syngeneic ovarian carcinoma models, we highlighted TAX2's ability to convert poorly immunogenic tumors into ones displaying effective anti-tumor T-cell immunity.
Mots clés
CD47, TSP-1, immunotherapy, ovarian cancer, peptide
Référence
Cancers (Basel). 2021 Oct 7;13(19):
